- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.11.2025 | 1.125 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.11.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.11.2025.ISIN NameCA74971G4016 RF... ► Artikel lesen | |
| PROSTALUND Aktie jetzt für 0€ handeln | |||||
| 03.11.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 209 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 24.10.25 | ProstaLund AB: PROSTALUND AB (publ) - Interim report January-September 2025 | 188 | GlobeNewswire (Europe) | Third quarterJuly 1 - September 30Net sales reached MSEK 2.2 (3.5)Operating profit/loss totaled MSEK -2.6 (-4.4)Loss after taxes MSEK -2.6 (-4.5)Earnings per share, before and after dilution amounted... ► Artikel lesen | |
| 15.10.25 | Delisting of ProstaLund AB from Nasdaq First North Growth Market | 298 | GlobeNewswire | ProstaLund AB has applied for its shares to be delisted from Nasdaq First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the shares of ProstaLund... ► Artikel lesen | |
| 12.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with the XEN Group for the market in the United Arab Emirates and Oman | 273 | GlobeNewswire (Europe) | ProstaLund has signed a collaboration agreement with the XEN Group, a prominent distributor of advanced innovative products with solid experience and contacts in the UAE and Oman. Through this partnership... ► Artikel lesen | |
| 10.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with Mayumana Healthcare for the Benelux market | 204 | GlobeNewswire (Europe) | ProstaLund has entered into a collaboration agreement with Mayumana Healthcare, a leading distributor of innovative urological solutions with strong expertise in the Benelux market. The partnership... ► Artikel lesen | |
| 21.08.25 | ProstaLund AB: ProstaLund AB - Interim Report January-June 2025 | 175 | GlobeNewswire (Europe) | April 1 - June 30Net sales reached MSEK 2.1 (2.8)Operating profit/loss totaled MSEK -6.3 (-7.2)Loss after taxes MSEK -6.5 (-7.1)Earnings per share, before and after dilution amounted to SEK -1.80 (-3.72)Cash... ► Artikel lesen | |
| 11.07.25 | The observation status for ProstaLund AB is updated | 307 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
Today... ► Artikel lesen | |
| 01.07.25 | The observation status for ProstaLund AB is updated | 259 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 30.05.25 | ProstaLund AB: ProstaLund AB - Interim report January-March 2025 | 252 | GlobeNewswire (Europe) | Januari 1 - March 31Net sales reached SEK 3,7 million (3,5)Operating result amounted to -5,0 MSEK (-4,7)Profit after tax amounted to -5,0 MSEK (-4,8)Earnings per share before and after dilution amounted... ► Artikel lesen | |
| 23.05.25 | XFRA 7PL0: WIEDERAUFNAHME/RESUMPTION | 456 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 23.05.25 | The observation status for ProstaLund AB is updated | 326 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 21.05.25 | Lift of Suspension in ProstaLund AB at FNSE | 346 | GlobeNewswire | 2025-05-21T15:00:36Z
Lifting of Suspension
At Trading Venue FNSE
Ended on:
2025-05-21T14:50:00Z
Ongoing: False
Comments: Nasdaq Stockholm has, to the
extent applicable, also decided to lift the suspension... ► Artikel lesen | |
| 20.05.25 | ProstaLund AB: First patients treated with CoreTherm Eagle | 337 | GlobeNewswire (Europe) | The first patients with benign prostatic hyperplasia have been successfully treated using our new CoreTherm® Eagle platform.
"We are very pleased that the first patients have been successfully treated... ► Artikel lesen | |
| 19.05.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 248 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 19.05.25 | Suspension of Trading in ProstaLund AB at FNSE | 312 | GlobeNewswire | 2025-05-19T07:01:39Z
Suspension
At Trading Venue FNSE
Due to Other
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent applicable, also decided to
suspend the trading in all other instruments... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 47,150 | -2,14 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Fresenius mit einem Kursziel von 56 Euro auf "Buy" belassen. Analyst Falko Friedrichs lobte in seiner am Donnerstag vorliegenden... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 40,710 | -2,33 % | SIEMENS HEALTHINEERS AG stürzt ab - ich rieche Gefahr! | ||
| FRESENIUS MEDICAL CARE | 39,620 | +1,20 % | BARCLAYS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für FMC von 47,50 auf 46,50 Euro gesenkt und die Einstufung auf "Equal Weight" belassen. Das Wachstum der Behandlungszahlen... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 18,860 | 0,00 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| PROGYNY | 17,800 | 0,00 % | INVO Fertility, Inc.: INVO Fertility's Wisconsin Clinic Joins Progyny Network | ||
| GERRESHEIMER | 18,100 | +5,54 % | Gerresheimers Abschluss unter dem Röntgenblick der BaFin | Die BaFin verschärft den Blick auf die Rechnungslegung der Gerresheimer AG. Sie kündigt an, die am 18.09.2025 gestartete Anlassprüfung des offengelegten Konzernabschlusses und Konzernlageberichts 2023/2024... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 26,600 | 0,00 % | Truist cuts Procept BioRobotics stock price target on lower forecasts | ||
| CARL ZEISS MEDITEC | 25,800 | -0,31 % | INDEX-MONITOR: Lufthansa verpasst Dax-Rückkehr - Nur Wechsel in MDax und SDax | ZUG (dpa-AFX) - Die Aktien von Lufthansa haben die Rückkehr in den deutschen Leitindex Dax verpasst. Wie der zur Deutschen Börse gehörende Index-Anbieter Stoxx am späten Mittwochabend mitteilte, bleibt... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,325 | 0,00 % | LifeStance Health Group, Inc. - 8-K, Current Report | ||
| ESSILORLUXOTTICA | 217,30 | -2,21 % | BARCLAYS stuft EssilorLuxottica auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für EssilorLuxottica mit einem Kursziel von 355 Euro auf "Overweight" belassen. Nutzzahlen zeigten, dass Smartglasses... ► Artikel lesen | |
| HEARTFLOW | 23,910 | 0,00 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| INNOVAGE | 10,610 | 0,00 % | InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025 | DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ("InnovAge" or the "Company") (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly... ► Artikel lesen | |
| NEUROPACE | 13,960 | 0,00 % | Why NeuroPace Stock Was Inching Higher on Wednesday | ||
| ECKERT & ZIEGLER | 15,290 | +0,53 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler kooperiert mit Molecular Partners bei der Entwicklung von Radio-DARPin-Therapeutika | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Kooperation/Vereinbarung
Eckert & Ziegler kooperiert mit Molecular Partners bei der Entwicklung von Radio-DARPin-Therapeutika
26.02.2026... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,310 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen |
Das Unternehmen PROSTALUND AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,001 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTALUND AB finden Sie auf Wallstreet Online.